dreamstime_l_17339305Statins (Lipitor, Crestor & others)  are effective, safe, and have been shown to prevent heart attacks and strokes.  Now, a new competitor is potentially coming to market, as it continues to show promise in lowering bad (LDL) cholesterol by 50-66%.  This group of medications are called anti-PSCK9 agents  & include Amgen’s evolocumab, alirocumab from Sanofi and Regeneron and Pfizer’s bococizumab.

These are injectible medications, they are showing promise and safety.  Further studies will confirm if they prevent heart attacks and strokes, and if they do so, they will offer an alternative agent for patients with heart disease, and in particular will be available for those are are unable to tolerate statins due to muscle or liver issues.

Read more  >>>>>HERE.